2023 Outlook
We now expect 2023 revenue of $2.7 billion (prior $2.95 billion) reflecting decreased CPP revenue, primarily driven by reduced consumer demand and ongoing elevated levels of customer
Reconciliation of GAAP to Non-GAAP 2023 Financial Guidance
(dollars in millions)
GAAP to Non-GAAP Guidance
GAAP
Full-year Impact of GAAP to Non-GAAP Adjustments
Adjusted EBITDA Guidance Reconciliation
An itemized reconciliation between projected GAAP net income and projected Adjusted EBITDA is as follows (in millions):
For the Year Ending
December 31,
The Company reiterates the following guidance for 2023:
Total revenue in the range of $440 million to $455 million.
Adjusted EBITDA(1) of $150 million to $160
Timken is increasing its 2023 outlook, with full-year earnings per diluted share now forecasted to be in the range of $5.90 to $6.40 and adjusted earnings per diluted share in the range
Reaffirming 2023 Outlook
Today, Sotera Health is reaffirming the 2023 outlook first provided on February 28, 2023. That outlook is:
Net revenues in the range of $1.055 to $1.090 billion, representing growth of